You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 58 No. 6, June 2001 TABLE OF CONTENTS
  Archives
  •  Online Features
  This Month in Archives of General Psychiatry
 This Article
 •PDF
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal

This Month in Archives of General Psychiatry

Arch Gen Psychiatry. 2001;58:528.

In a double-blind, randomized, placebo-controlled trial, Soares et al (SEE ARTICLE) report the efficacy of transdermal 17-{beta} estradiol for the treatment of minor and major depression in perimenopausal women. Subjects showed a significant improvement in mood, regardless of the type of depression. Treatment was generally well tolerated. After a 4-week washout period, patients treated with estradiol sustained antidepressant benefit, despite the recrudescence of vasomotor symptoms.

A commentary by Stahl is included. (SEE ARTICLE)

The occurrence of antidepressant-induced mania is a key issue in the clinical management of bipolar disorder. In this study on the role of the serotonin transporter protein gene in predicting this undesirable effect of antidepressant treatment, Mundo et al (SEE ARTICLE) reported that patients carrying 1 or 2 copies of the short variant of the gene (which also is considered to generate less gene expression) are more likely to develop antidepressant-induced mania. If these results are replicated, the variant of the serotonin transporter protein gene may become an important predictor of abnormal response to medication in patients with bipolar disorder.

Glial cells greatly outnumber neurons in the cortex and are vital for normal neuronal function. In a postmortem investigation, Cotter et al (SEE ARTICLE) examined glial cell density and neuronal size in the anterior cingulate cortex among subjects with major depression, schizophrenia, bipolar disorder, and normal controls. Compared with controls, subjects with major depression showed reduced glial cell density and reduced neuronal size in layer 6. There was also some evidence for reduced glial cell density in schizophrenia.

Recent neuroimaging studies of panic disorder have suggested dysfunction in the inhibitory GABA neuronal system. Consistent with this previous work, Goddard et al (SEE ARTICLE) report abnormal reductions in occipital cortex GABA levels in a group of unmedicated patients with active panic disorder, using a novel magnetic resonance spectroscopic technique. The data indicate that low occipital cortex GABA is associated with the panic disorder diagnosis itself rather than illness severity.

Patients with mental disorders are at risk for elevated rates of cardiovascular mortality; however, little is known about the possible contributory role of poor quality of medical care. Examining a large cohort of Medicare patients hospitalized for myocardial infarction, Druss et al (SEE ARTICLE) found that deficits in use of 5 established indicators of medical quality appeared to explain a substantial portion of the excess mortality experienced by patients with mental disorders in the year after myocardial infarction.

Individuals with schizophrenia tend to smoke more often and more heavily than average, but nonetheless epidemiological studies have found their risk of lung cancer decreased. Could some schizophrenia vulnerability gene protect them from cancer despite increased smoking? In the largest study to date, Lichtermann et al (SEE ARTICLE) found that persons with schizophrenia in Finland indeed ran a higher risk of cancer than the general population, and obviously cannot escape this tragic consequence of tobacco and alcohol consumption. However, cancer risk in their biological relatives was decreased, and this could well be compatible with a combined schizophrenia vulnerability and cancer protective gene.

A commentary by Jablensky and Lawrence is included. (SEE ARTICLE)

In a family study of parents of patients with childhood-onset schizophrenia (COS), Asarnow et al (SEE ARTICLE) report that the parents of COS probands had an increased risk for schizophrenia and schizotypal personality disorder compared with parents of attention-deficit/hyperactivity disorder and community control probands. The risk of avoidant personality disorder was also increased in parents of COS probands compared with parents of community control probands. The psychiatric disorders that do and do not aggregate in the parents of COS probands are remarkably similar to the disorders that aggregate in parents of adult-onset schizophrenia probands, providing compelling evidence for the etiological continuity between COS and adult-onset schizophrenia.

Personality disorders are frequent among psychiatric patients. However, the prevalence in the common population is largely unknown. In the first study of a larger representative sample of the common population, Torgersen et al (SEE ARTICLE) have found that 1 of 8 individuals in the main city of Norway has a personality disorder.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2001 American Medical Association. All Rights Reserved.